霍奇金淋巴瘤：现状与临床试验建议
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.
作者信息
Diefenbach Catherine S, Connors Joseph M, Friedberg Jonathan W, Leonard John P, Kahl Brad S, Little Richard F, Baizer Lawrence, Evens Andrew M, Hoppe Richard T, Kelly Kara M, Persky Daniel O, Younes Anas, Kostakaglu Lale, Bartlett Nancy L
机构信息
Affiliations of authors: NYU Perlmutter Cancer Center, New York, NY (CSD); BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada (JMC); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY (JWF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Department of Medicine, Washington University, St. Louis, MO (BSK, NLB); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), Tufts Cancer Center and Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA (AME); Stanford Cancer Institute, Stanford University Medical School, Stanford, CA (RTH); Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, NY (KMK); Department of Medicine, University of Arizona Cancer Center, Tucson, AZ (DOP); Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY (AY); Department of Radiology, Mount Sinai Hospital, New York, NY (LK).
出版信息
J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw249. Print 2017 Apr.
The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.
国家临床试验网络淋巴系统恶性肿瘤临床试验规划会议（CTPM）于2014年11月召开。CTPM的范围是在淋巴系统肿瘤中对具有临床意义的问题进行优先级排序，并促进制定能带来基于生物学认知且可能改变临床实践的临床试验策略。CTPM霍奇金淋巴瘤（HL）小组委员会的这篇综述讨论了HL当前面临的临床挑战，概述了HL患者从早期到晚期的当前护理标准，并调查了关于生物标志物的当前科学情况以及正在进行的临床试验格局。最后，我们提出了HL中未满足的需求领域，并阐明了有前景的治疗策略，以指导整个国家临床试验网络（NCTN）未来HL临床试验的规划。
Zotero 插件